Annaly Capital Management
A director has purchased 300,000 shares of
Annaly Capital Management, Inc. (NYSE:
NLYAon
A director scooped up 75,000 shares of this London-based insurance and outsourcing company last week. At $100.79 per share, that was worth around $7.56 million, and it boosted his stake to more than 140,000 shares. Aon posted second-quarter results last week that included an earnings beat.
The market cap of
Aon Plc (NYSE:
AON) is around $28.5 billion, and the dividend yield is about 1.2 percent. The price-to-earnings (P/E) ratio is less than the industry average and the long-term earnings per share (EPS) growth forecast is greater than 11 percent. The share price ended last week at $101.32.
See also:4 Stocks For Socially Responsible InvestorsColfax
One director has bought a total of more than 261,000
Colfax Corp (NYSE:
CFX) shares ranging between $38.11 and $38.83 apiece so far this month. The total for those transactions came to about $10 million. Colfax recently
named a new chief executive officer.
This Maryland-based industrial manufacturing and engineering company has a market cap near $5.0 billion. It offers no dividend. The operating margin is greater than the industry average but the long-term EPS growth forecast is less than 3 percent. Shares ended last week at $14.12, so the buys seem well-timed.
Enterprise Products Partners
The
Enterprise Products Partners L.P. (NYSE:
EPDGM
A director purchased 32,000 shares of
General Motors Company (NYSE:
GM) at the end of July for $31.84 apiece. That cost him a little more than $1 million, and it followed the release of a stronger-than-expected
second-quarter report .
This automaker has a market cap of more than $50 billion and a dividend yield near 4.6 percent. The P/E ratio is less than the industry average and the long-term EPS growth forecast is nearly 21 percent. Note that shares ended Friday's trading session still near the purchase price, at $31.74.
See also:17 Mutual Funds To Ride The Tech WaveValeant Pharmaceuticals
The chief financial officer recently picked up more than 7,800
Valeant Pharmaceuticals Intl Inc (NYSE:
VRXAt the time of this writing, the author had no position in the mentioned equities.
Keep up with all the latest breaking news and trading ideas by following Benzinga on
Twitter.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
